http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013102019-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35d9ddd9f56e7f62be5d219a16cc62e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1290fbfbfd3295fb06d93acc2903312 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e72837de81999e7e72cb78d59d19e28 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-908 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-28 |
| filingDate | 2012-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_120842bad7d04bc080b6162fba36c829 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8df78eb0e69f78195a69628fd98f70e2 |
| publicationDate | 2013-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2013102019-A1 |
| titleOfInvention | Assessing the risk of a major adverse cardiac event in patients with chest pain |
| abstract | Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a control value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from control population. Such comparison can also be used to determine the near term treatment of the patient. |
| priorityDate | 2003-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 206.